Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6Bio SCHEMBL21067440 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL14088703 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| SCHEMBL22300057 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL30249771 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL4997980 | 1.00 | AGTR1 (0.48) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL29975657 | 0.99 | AGTR1 (0.47) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| 6Bio SCHEMBL27160645 | 0.99 | AGTR1 (0.47) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| Indirubin 2 SCHEMBL22215161 | 0.91 | AGTR1 (0.49) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| Indirubin 2 SCHEMBL30380962 | 0.91 | AGTR1 (0.49) | AGTR1IDO1TDO2LRRK2NTRK1 | |
| SCHEMBL3850179 | 0.91 | LRRK2 (0.50) | AGTR1IDO1TDO2LRRK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3384007-B1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-03-27 | — | — | EP | claimed |
| US-20170191038-A1 | TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE | HONG GUAN LTD (CN) | 2017-07-06 | — | — | US | claimed |
| EP-3964565-B1 | AN IN VITRO METHOD OF DIFFERENTIATING A HUMAN PLURIPOTENT STEM CELL POPULATION INTO A CARDIOMYOCYTE CELL POPULATION | NCARDIA B V (NL) | 2026-04-08 | — | — | EP | disclosed |
| US-12180509-B2 | Methods for reprograming non-pluripotent cells into pluripotent stem cells | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-12-31 | — | — | US | disclosed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240226063-A1 | SOLUBLE ANALOGUES OF 6BIO THEREOF AND IMPLEMENTATION THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228467-A1 | INDIRUBIN COMPOUNDS AND METHODS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) | 2024-07-11 | — | — | US | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12018278-B2 | Methods for chemically induced lineage reprogramming | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-06-25 | — | — | US | disclosed |
| EP-4329747-A1 | SOLUBLE ANALOGUES OF 6BIO THEREOF AND IMPLEMENTATION THEREOF | Jawaharlal Nehru Centre For Advanced Scientific Research (IN) | 2024-03-06 | — | — | EP | disclosed |
| US-20230183643-A1 | COMPOSITIONS AND METHODS FOR PRODUCING PLACENTAL CELLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-06-15 | — | — | US | disclosed |
| US-20110130706-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2010013168-A1 | 3',6-SUBSTITUTED INDIRUBINS AND THEIR BIOLOGICAL APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-04 | — | — | WO | disclosed |
| EP-2149553-A1 | 3', 6-substituted indirubins and their biological applications | Centre National De La Recherche Scientifique (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-20080194024-A1 | Culture of Non-Embryonic Cells at High Cell Density | ABT HOLDING COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-20080194024-A1 | Culture of Non-Embryonic Cells at High Cell Density | ABT HOLDING COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-20080194021-A1 | Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells | ABT HOLDING COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-20080194021-A1 | Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells | ABT HOLDING COMPANY | 2008-08-14 | — | — | US | disclosed |
| WO-2007117262-A2 | CULTURE OF NON-EMBRYONIC CELLS AT HIGH CELL DENSITY | ATHERSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007016485-A2 | USE OF A GSK-3 INHIBITOR TO MAINTAIN POTENCY OF CULTURED CELLS | ATHERSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180509-B2 | Methods for reprograming non-pluripotent cells into pluripotent stem cells | AHCY, BHMT, SHMT1 | AGTR1 4279/4885IDO1 1607/4885TDO2 4093/4885 |
| US-20240228467-A1 | INDIRUBIN COMPOUNDS AND METHODS THEREOF | ATG7, SQSTM1, BECN1 | AGTR1 4746/4885IDO1 66/4885TDO2 331/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | AGTR1 3439/4885IDO1 4516/4885TDO2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.